APA (7th ed.) Citation

Fleischmann, M., Diefenhardt, M., Nicolas, A. M., Rödel, F., Ghadimi, M., Hofheinz, R., . . . Fokas, E. (2022). ACO/ARO/AIO-21-capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer patients: A phase I trial of the German rectal cancer study group. Clinical and translational radiation oncology, 34, . https://doi.org/10.1016/j.ctro.2022.04.003

Chicago Style (17th ed.) Citation

Fleischmann, Maximilian, Markus Diefenhardt, Adele M. Nicolas, Franz Rödel, Michael Ghadimi, Ralf-Dieter Hofheinz, Florian Greten, Claus Rödel, and Emmanouil Fokas. "ACO/ARO/AIO-21-capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group." Clinical and Translational Radiation Oncology 34 (2022). https://doi.org/10.1016/j.ctro.2022.04.003.

MLA (9th ed.) Citation

Fleischmann, Maximilian, et al. "ACO/ARO/AIO-21-capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group." Clinical and Translational Radiation Oncology, vol. 34, 2022, https://doi.org/10.1016/j.ctro.2022.04.003.